Solid Self Nano-Emulsifying Drug Delivery System of Dasatinib: Optimization, <i>In-vitro</i> , <i>Ex-vivo</i> and <i>In-vivo</i> assessment

<b>Aim:</b> Dasatinib (DST) is an oral tyrosine kinase inhibitor with poor aqueous solubility. To outwit this issue, a solid self-nano emulsifying drug delivery system (S-SNEDDS) of DST was formulated.<b>Methods:</b> I-optimal mixture design was used for optimization of DST-loaded SNEDDS using Linalool, Cremophor RH40 and Transcutol P. S-SNEDDS underwent physicochemical characterization, <i>in-vitro</i> release and <i>ex-vivo</i> permeation, cell-based assays and pharmacokinetic study.<b>Results:</b> DST-S-SNEDDS showed globule size and PDI of 141.53 ± 5.371 nm and 0.282 ± 0.020, respectively. DST-S-SNEDDS revealed significantly lower IC₅₀ (1.825 μg/mL) than free DST (7.298 μg/mL) in MDA-MB-231. <i>In-vivo</i> pharmacokinetic study revealed 1.94-fold increment in AUC_0-t for the DST-S-SNEDDS group than free DST.<b>Conclusion:</b> S-SNEDDS could be promising approach for improving bioavailability and efficacy of DST.